Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02696 HENLIUS
RTNominal unchange15.260 0.000 (0.000%)
Others

18/10/2019 14:45

Henlius Biotech (02696) drug gets clinical trial approval

[ET Net News Agency, 18 October 2019] Shanghai Henlius Biotech, Inc. (02696) said it
has obtained the clinical trial application approval from the National Medical Products
Administration for the new drug developed by the company - HLX55 Monoclonal Antibody for
Injection used for metastatic or recurrent solid tumour treatment.
HLX55 is a bio-innovative drug that the company licensed-in from Kolltan
Pharmaceuticals, Inc. for exclusive development and commercialisation in various regions
across Asia and a humanised monoclonal antibody developed for targeting cMET. (RC)

Back to Others

Remark: Real time quote last updated: 23/04/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.